Gourt > Health > Pharmacy > Drugs and Medications > E > Enfuvirtide
Enfuvirtide (INN) is an HIV fusion inhibitor, the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection. It is marketed under the trade name Fuzeon (Roche).
Enfuvirtide therapy costs an estimated USD$25,000 per year in the United States. Its cost and inconvenient dosing regimen are factors behind its use as a reserve, for "salvage" therapy in patients with multi-drug resistant HIV.
History
Pharmaceutical company Trimeris began development on enfuvirtide in 1996 and initially designated it T-20. In 1999, Trimeris entered into partnership with Hoffmann-La Roche to complete the development of the drug. It was approved by the U.S. Food and Drug Administration (FDA) on March 13, 2003 as the first HIV fusion inhibitor, a new class of antiretroviral drugs. It was approved on the basis of two studies (TORO 1 and TORO 2) which compared the effect of optimized regimens of antiretroviral medication with and without the addition of enfuvirtide on serum viral load. More on [ Enfuvirtide ]
Fuzeon - Roche - Official pharmaceutical website for Fuzeon(enfuvirtide) a drug designed to block HIV fusion in treatment-experienced people.
Meta Description: [ Fuzeon.com is the official Web site for FUZEON — the first HIV fusion inhibitor. Fuzeon.com provides detailed information about FUZEON for people living with HIV and healthcare professionals. ]
Fuzeon Consumer Information - FDA - Patient FAQ in html format with a link to approved labeling in pdf format.
MedlinePlus: Enfuvirtide (Systemic) - Provides information on usage, precautions, side effects and brand names when available. Data provided by various government agencies and health-related organizations.
Meta Description: [ Enfuvirtide(Systemic) ]
| SUHAIL GALADARI & SHAHID AFRIDI | |
| Next Video | |
